Drugs / ELIXCYTE
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02933827 | May 2018 → Apr 2019 | chronic kidney disease | UnicoCell Biomed CO. LTD | Completed | No outcome recorded |
| Phase 1/2 | NCT02784964 | Mar 2016 → Jul 2018 | osteoarthritis, knee | UnicoCell Biomed CO. LTD | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05526001 | Jul 2023 → May 2026 overdue | osteoarthritis, knee | UnicoCell Biomed CO. LTD | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ELIXCYTE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05526001 ↗ |
| Modality | Cell therapy | “allogeneic adipose-derived stem cells (ADSCs)” PMID 34717765 ↗ Oct 2021 |
| Route | Other | “intra-articular (IA) injection” PMID 34717765 ↗ Oct 2021 |